COVID-19 Information

Edit Entry | Edit CV

Anna N. A. Tosteson, ScD

Title(s)
Interim Director and Professor of The Dartmouth Institute
Professor of Medicine
Professor of Community and Family Medicine
James J. Carroll 1948 Professor of Oncology

Additional Titles/Positions/Affiliations
Director, Comparative Effectiveness Research Program, The Dartmouth Institute for Health Policy and Clinical Practice
Associate Director for Population Sciences, Norris Cotton Cancer Center
Associate Director, SYNERGY, Dartmouth's Clinical and Translational Science Institute

Department(s)
The Dartmouth Institute
Medicine
Community and Family Medicine

Education
Biostatistics (Health Decision Sciences), Harvard University, ScD
Biostatistics, Harvard University, MS
Statistics & Biometry, Cornell University, BS

Programs
Norris Cotton Cancer Center
SYNERGY
The Dartmouth Institute for Health Policy and Clinical Practice

Contact Information

Dartmouth Medical School
HB 7505
One Medical Center Drive
Lebanon NH 03756

Office: WTRB 526, DHMC
Phone: 603-653-3568
Email: Anna.Tosteson@dartmouth.edu

Assistant: Christopher Jacobs
Asst. Phone: 603-653-0802
Asst. Email: Christopher.R.Jacobs@Dartmouth.EDU


Professional Interests

Dr. Anna Tosteson is a decision scientist and health services researcher who studies how the diffusion of innovations in health care are changing health, costs and quality of care. Through study of diverse data sources including registries, clinical and epidemiological studies, and administrative claims data, she seeks insights into the long-term clinical and economic effects of alternative approaches to health care delivery with a focus on cancer screening, musculoskeletal disease, and women’s health.

Grant Information

Promoting follow-up of abnormal cancer screening tests using population-based systems to support stepped care multilevel intervention. (NCI: U01CA225451 )

Risk-based breast cancer screening and surveillance in community practice. (NCI, P01CA154292)

Courses Taught

PH 119/121; QBS 140 Decision and Cost-Effectiveness Analysis


Selected Publications

 

Sacubitril/Valsartan vs. ACEi/ARB at Hospital Discharge and 5-Year Survival in Older Patients with Heart Failure with Reduced Ejection Fraction: A Decision Analysis Approach.
Gilstrap L, Zipkin RJ, Barnes JA, King A, O'Malley AJ, Gaziano TA, Tosteson ANA
Am Heart J. 2022 May 4; pii: S0002-8703(22)00082-5. doi: 10.1016/j.ahj.2022.04.007. Epub 2022 May 4.
PMID: 35525261

Factors Influencing Telemedicine Use at a Northern New England Cancer Center During the COVID-19 Pandemic.
Mackwood MB, Tosteson TD, Alford-Teaster JA, Curtis KM, Lowry ML, Snide JA, Zhao W, Tosteson ANA
JCO Oncol Pract. 2022 Apr 21;:OP2100750. doi: 10.1200/OP.21.00750. Epub 2022 Apr 21.
PMID: 35446680

Breast Density Knowledge in a Screening Mammography Population Exposed to Density Notification.
Smith RE, Sprague B, Henderson LM, Kerlikowske K, Miglioretti DL, Buist DSM, Wernli KJ, Onega T, Schifferdecker K, Jackson-Nefertiti G, Johnson D, Budesky J, Tosteson ANA
J Am Coll Radiol. 2022 May;19(5):615-624. doi: 10.1016/j.jacr.2022.02.025. Epub 2022 Mar 24.
PMID: 35341697

Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography.
Ho TH, Bissell MCS, Kerlikowske K, Hubbard RA, Sprague BL, Lee CI, Tice JA, Tosteson ANA, Miglioretti DL
JAMA Netw Open. 2022 Mar 1;5(3):e222440. doi: 10.1001/jamanetworkopen.2022.2440. Epub 2022 Mar 1.
PMID: 35333365

Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
Lowry KP, Geuzinge HA, Stout NK, Alagoz O, Hampton J, Kerlikowske K, de Koning HJ, Miglioretti DL, van Ravesteyn NT, Schechter C, Sprague BL, Tosteson ANA, Trentham-Dietz A, Weaver D, Yaffe MJ, Yeh JM, Couch FJ, Hu C, Kraft P, Polley EC, Mandelblatt JS, Kurian AW, Robson ME, Breast Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET), in collaboration with the Breast Cancer Surveillance Consortium (BCSC), and the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium.
JAMA Oncol. 2022 Apr 1;8(4):587-596. doi: 10.1001/jamaoncol.2021.6204.
PMID: 35175286

A Procedure for Eliciting Women's Preferences for Breast Cancer Screening Frequency.
Grayek E, Yang Y, Fischhoff B, Schifferdecker KE, Woloshin S, Kerlikowske K, Miglioretti DL, Tosteson ANA
Med Decis Making. 2022 Jan 22;:272989X211073320. doi: 10.1177/0272989X211073320. Epub 2022 Jan 22.
PMID: 35067067

Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population.
Kerlikowske K, Chen S, Golmakani MK, Sprague BL, Tice JA, Tosteson ANA, Rauscher GH, Henderson LM, Buist DSM, Lee JM, Gard CC, Miglioretti DL
J Natl Cancer Inst. 2022 May 9;114(5):676-685. doi: 10.1093/jnci/djac008.
PMID: 35026019

Comparing Mammographic Density Assessed by Digital Breast Tomosynthesis or Digital Mammography: The Breast Cancer Surveillance Consortium.
Tice JA, Gard CC, Miglioretti DL, Sprague BL, Tosteson ANA, Joe BN, Ho TH, Kerlikowske K
Radiology. 2022 Feb;302(2):286-292. doi: 10.1148/radiol.2021204579. Epub 2021 Nov 23.
PMID: 34812671

Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield.
Onega T, Zhu W, Kerlikowske K, Miglioretti DL, Lee CI, Henderson LM, Tosteson ANA, Wernli KJ, diFlorio R, Weaver DL, Buist DSM
Breast Cancer Res Treat. 2022 Jan;191(1):177-190. doi: 10.1007/s10549-021-06418-x. Epub 2021 Oct 22.
PMID: 34686934

Breast Biopsy Recommendations and Breast Cancers Diagnosed during the COVID-19 Pandemic.
Lowry KP, Bissell MCS, Miglioretti DL, Kerlikowske K, Alsheik N, Macarol T, Bowles EJA, Buist DSM, Tosteson ANA, Henderson L, Herschorn SD, Wernli KJ, Weaver DL, Stout NK, Sprague BL
Radiology. 2022 May;303(2):287-294. doi: 10.1148/radiol.2021211808. Epub 2021 Oct 19.
PMID: 34665032

View more publications on PubMed